CURE staff

A 30-year study reveals one in six AYA cancer survivors develop a new primary neoplasm, with risks highest for breast and oral cancer survivors.

PDS01ADC showed high response rates in metastatic colorectal cancer in a phase 2 trial after prior treatment.

Emactuzumab improved tumor response and function in TGCT, showing rapid, durable benefits in a phase 3 trial with a short-course treatment approach.

Daraxonrasib improved overall survival versus chemotherapy in metastatic pancreatic cancer.

Gotistobart reduced risk of death by 54% and doubled 12-month survival vs chemotherapy in advanced squamous NSCLC after prior treatment.

Nuvalent submitted an NDA for neladalkib to the FDA for patients with previously treated ALK-positive non-small cell lung cancer, based on ALKOVE-1 trial data showing activity.

New research shows adults over 80 with early-stage lung cancer can achieve surgical outcomes and quality of life comparable to younger patients.

The FDA fully approved Tecartus for adult patients with relapsed or refractory mantle cell lymphoma based on high response rates in the ZUMA-2 trial.

A new study shows Signatera ctDNA testing may identify older patients with ER+/HER2- breast cancer who can manage their care without invasive surgery.

A phase 3 trial finds anbenitamab and docetaxel improve response rates in patients with HER2-positive breast cancer and offer a safer delivery.

Eight patients with NSCLC treated with ateganosine plus Libtayo had over 2-year survival after prior therapies, based on phase 2 THIO-101 trial data.

FDA fast tracked ZW191 for platinum-resistant ovarian cancer, aiming to speed development of a potential new option for patients with limited treatments.

Coverage from NCCN 2026 highlights global care delivery, younger patient needs, survivorship strategies and safer immunotherapy management.

Global efforts in prevention, early detection and collaboration are improving cancer care access, but disparities persist based on where patients live.

FDA approves a PD-L1 test to help identify patients with esophageal or gastroesophageal junction (GEJ) cancer who may benefit from Keytruda.

FDA approved Lifyorli plus Abraxane, improving survival in platinum-resistant ovarian, fallopian tube and peritoneal cancers.

Five-year ICESECRET data show high recurrence-free rates with cryoablation for small kidney tumors, supporting a minimally invasive treatment option.

New findings from the phase 3 SENTRY trial offer encouraging news for patients with myelofibrosis.

Topical HT-001 reduced rash and irritation from EGFR therapies with low levels in the bloodstream and no serious side effects in patients with cancer.

Zegfrovy helped patients live longer without cancer growth and improved tumor response compared with chemotherapy in first-line lung cancer treatment.

An overview of stage 1 lymphocyte-rich Hodgkin lymphoma covers diagnosis, treatment options and side effects to help guide patient care decisions.

Dr. Hope Rugo and advocate Jonise Louis discuss new ADCs, biomarker testing, and patient-centered dosing for metastatic triple-negative breast cancer.

High-risk essential thrombocythemia is manageable with treatment focused on preventing blood clots and maintaining safe platelet levels.

FDA approves Opdivo with AVD for stage 3 or 4 Hodgkin lymphoma after trial shows improved progression-free survival versus comparator in untreated patients.

Talzenna plus Xtandi improved progression-free survival in metastatic prostate cancer, delaying disease worsening in a phase 3 trial.

A phase 3 study shows pimicotinib shrinks tumors and improves pain, stiffness and mobility in adults with unresectable tenosynovial giant cell tumors.

NCCN guidelines now include plus BCG for certain BCG-unresponsive bladder cancer patients, expanding treatment options.

The FOURLIGHT-1 study found that atirmociclib plus Faslodex significantly improved progression-free survival in patients with HR+/HER2- metastatic breast cancer.

A UCLA study found CAR-NKT cells eliminated endometrial tumors in models and showed stronger activity than existing immunotherapies, supporting further clinical development.

Survey shows 92% of eligible adults support coverage for colorectal cancer blood tests to improve screening access and adherence.